GenVec Inc. (NASDAQ:GNVC)’s stock is going to reverse split on Thursday, December 1st. The 1-10 reverse split was announced on Wednesday, November 16th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, November 30th.

GenVec (NASDAQ:GNVC) opened at 0.38 on Friday. GenVec has a 12-month low of $0.27 and a 12-month high of $3.69. The stock’s market cap is $8.64 million. The firm has a 50-day moving average of $0.37 and a 200-day moving average of $0.55.

Several brokerages have recently issued reports on GNVC. Zacks Investment Research upgraded shares of GenVec from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a report on Tuesday, November 8th. Roth Capital restated a “buy” rating and issued a $2.00 target price (down previously from $8.00) on shares of GenVec in a report on Tuesday, July 26th.

An institutional investor recently bought a new position in GenVec stock. Sabby Management LLC purchased a new position in GenVec Inc. (NASDAQ:GNVC) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,625,435 shares of the biopharmaceutical company’s stock, valued at approximately $931,000. Sabby Management LLC owned approximately 7.15% of GenVec at the end of the most recent quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

GenVec Company Profile

GenVec, Inc (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria.

5 Day Chart for NASDAQ:GNVC

Receive News & Stock Ratings for GenVec Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec Inc. and related stocks with our FREE daily email newsletter.